Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Trial Profile

An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Droxidopa (Primary)
  • Indications Orthostatic hypotension
  • Focus Therapeutic Use
  • Sponsors Chelsea Therapeutics
  • Most Recent Events

    • 06 Jan 2017 Results (n=907) assessing CV safety of Droxidopa using patient data from NOH-301, NOH-302, NOH-303, NOH-304 and NOH-306 trials, published in the American Journal of Cardiology.
    • 21 Apr 2016 Results of an integrated analysis from five trials assessing cardiovascular safety presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results from NOH306 and NOH303 trials presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top